
Patients with chronic hepatitis C virus genotype 1 infection and with or without cirrhosis achieved high rates of sustained virologic response after 12 weeks of treatment with a combination of the direct-acting-antiviral drugs daclatasvir, asunaprevir, and beclabuvir, researchers report.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/1GjUD2P-Ics/150505121318.htm